Got it. So although both drugs fall into a similar (and new) class of oncology drugs that work based on certain genetic markers, they have very different mechanisms of action. Sounds like leronlimab may be more complementary with Keytruda, as the CCR5 inhibitor would slow/halt metastasis while Keytruda allowed the immune system to attack the existing cancer cells.
News 
Market Data 
Discover 
